The Kava Anxiety Depression Spectrum Study (KADSS): A randomized, placebo-controlled crossover trial using an aqueous extract of Piper methysticum

Psychopharmacology

Volumn 205, Issue 3, 2009, Pages 399-407

  Sarris, J ^a   Kavanagh, D J ^b   Byrne, G ^a   Bone, K M ^c   Adams, J ^a   Deed, G ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^c UNIVERSITY OF NEW ENGLAND   (Australia)

Author keywords

Anxiety; Aqueous extract; Depression; Herbal medicine; Kava; Piper methysticum

Indexed keywords

KAVA EXTRACT; PLACEBO;

ADULT; ARTICLE; BECK ANXIETY INVENTORY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FEMALE; FLU LIKE SYNDROME; GENERALIZED ANXIETY DISORDER; HAMILTON ANXIETY SCALE; HUMAN; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH DISCOMFORT; TRANQUILIZING ACTIVITY;

ADULT; ANTI-ANXIETY AGENTS; ANTIDEPRESSIVE AGENTS; ANXIETY; CROSS-OVER STUDIES; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KAVA; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 67651005824     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-009-1549-9     Document Type: Article

References (34)

1. J Alonso MC Angermeyer S Bernert R Bruffaerts TS Brugha H Bryson 2004 Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project Acta Psychiatr Scand Suppl 420 21 27
2. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th 'text revision' edn. American Psychiatric Association
3. AT Beck C Ward M Mendelson 1961 Beck depression inventory (BDI) Arch Gen Psychiatry 4 561 571
4. AT Beck N Epstein G Brown RA Steer 1988 An inventory for measuring clinical anxiety: psychometric properties J Consult Clin Psychol 56 893 897
5. Blumenthal (2004) The ABC clinical guide to herbs. American Botanical Council
6. RJ Boerner H Sommer W Berger U Kuhn U Schmidt M Mannel 2003 Kava-Kava extract LI 150 is as effective as opipramol and buspirone in generalised anxiety disorder-an 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients Phytomedicine 10 Suppl 4 38 49
7. G Chouinard 2004 Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound J Clin Psychiatry 65 Suppl 5 7 12
8. DL Clouatre 2004 Kava kava: examining new reports of toxicity Toxicol Lett 150 85 96
9. Coulter D (2007) Assessment of the risk of hepatotoxicity with kava products. WHO Appointed Committee
10. B Currie A Clough 2003 Kava hepatotoxicity with western herbal products: does it occur with traditional kava use? MJA 178 412 422
11. Y Dundar S Dodd J Strobl A Boland R Dickson T Walley 2004 Comparative efficacy of newer hypnotic drugs for the short-term management of insomnia: a systematic review and meta-analysis Hum Psychopharmacol 19 305 322 (Pubitemid 39106872)
12. M Hamilton 1959 The assessment of anxiety states by rating Br J Med Psychol 32 50 55
13. RC Kessler MB Keller HU Wittchen 2001 The epidemiology of generalized anxiety disorder Psychiatr Clin North Am 24 19 39
14. V Lebot 2006 The quality of Kava consumed in the South Pacific HerbalGram 71 34 37
15. Y Lecrubier 2007 Widespread underrecognition and undertreatment of anxiety and mood disorders: results from 3 European studies J Clin Psychiatry 68 Suppl 2 36 41
16. JL Martin M Sainz-Pardo TA Furukawa E Martin-Sanchez T Seoane C Galan 2007 Benzodiazepines in generalized anxiety disorder: heterogeneity of outcomes based on a systematic review and meta-analysis of clinical trials J Psychopharmacol 21 774 782
17. JM Mathews AS Etheridge JL Valentine SR Black DP Coleman P Patel J So LT Burka 2005 Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro Drug Metab Dispos 33 1555 1563
18. K Mitte P Noack R Steil M Hautzinger 2005 A meta-analytic review of the efficacy of drug treatment in generalized anxiety disorder J Clin Psychopharmacol 25 141 150
19. S Montgomery M Asberg 1979 New depression scale designed to be sensitive to change Br J Psychiatry Suppl 134 382 389
20. S Morris 2008 Estimating effect sizes from pretest-posttest-control group designs Organ Res Methods 11 364 386
21. P Nerurkar K Dragull C Tang 2004 In vitro toxicity of Kava alkaloid, pipermethysticine, in HepG2 cells compared to kavalactones Toxicol Sci 79 106 111
22. MH Pittler E Ernst 2000 Efficacy of kava extract for treating anxiety: systematic review and meta-analysis J Clin Psychopharmacol 20 84 89
23. Pittler MH, Ernst E (2006) Kava extract for treating anxiety. Cochrane Database Syst Rev: CD003383
24. MA Posternak M Zimmerman 2005 Is there a delay in the antidepressant effect? A meta-analysis J Clin Psychiatry 66 148 158
25. K Rickels M Rynn 2002 Pharmacotherapy of generalized anxiety disorder J Clin Psychiatry 63 Suppl 14 9 16
26. LN Robins J Wing HU Wittchen JE Helzer TF Babor J Burke A Farmer A Jablensky R Pickens DA Regier N Sartorius LH Towle 1989 The Composite International Diagnostic Interview: an epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures Arch Gen Psychiatry 45 1069 1077
27. J Sarris DJ Kavanagh G Deed KM Bone 2009 St. John's wort and Kava in treating major depressive disorder with comorbid anxiety: a randomised double-blind placebo-controlled pilot trial Hum Psychopharmacol 24 41 48
28. YN Singh AK Devkota 2003 Aqueous kava extracts do not affect liver function tests in rats Planta Med 69 496 499
29. C Stevinson A Huntley E Ernst 2002 A systematic review of the safety of kava extract in the treatment of anxiety Drug Safety 25 251 261
30. R Thompson W Ruch R Hasenöhrl 2004 Enhanced cognitive performance and cheerful mood by standardized extracts of Piper methysticum (Kava-kava) Hum Psychopharmacol 19 243 250
31. P Tyrer D Baldwin 2006 Generalised anxiety disorder Lancet 368 2156 2166
32. Vanuatu Kava Act (2002) Republic of Vanuatu No.7
33. HU Wittchen 2002 Generalized anxiety disorder: prevalence, burden, and cost to society Depress Anxiety 16 162 171
34. S Witte D Loew W Gaus 2005 Meta-analysis of the efficacy of the acetonic Kava-kava extract WS1490 in patients with non-psychotic anxiety disorders Phytother Res 19 183 188